Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Omalizumab for Atopic Dermatitis

Omalizumab for Atopic Dermatitis Opinion EDITORIAL Overtreatment or Lifesaver? Ann Chen Wu, MD, MPH Atopic dermatitis is a chronic inflammatory skin disease siderable price discounts or medication targeted to specific se- that affects 15% to 20% of children and 1% to 3% of adults vere subgroups. No studies have been conducted to establish worldwide. Omalizumab, a medication administered by the cost-effectiveness of omalizumab for atopic dermatitis, but subcutaneous injection every 2 to 4 weeks, was approved for with current pricing, omalizumab for this purpose may not be moderate-to-severe persis- cost-effective. In general, asthma is a more severe disease than tent asthma in patients aged atopicdermatitis.Asthmawasthecauseof383 000deathsworld- Related article page 29 6 years or older by the US wide in 2015 according to the World Health Organization, com- Food and Drug Administration in 2003. Atopic dermatitis in pared with a slightly increased risk of death from other diseases children is often IgE mediated, and omalizumab is an anti- in patients with atopic dermatitis. Multiple cost-effectiveness IgE medication that binds to human IgE and thus limits mast studiesofasthmarecommendreducingomalizumabcoststojus- cell degranulation and inhibits the release of inflammatory me- tify its use; the same argument could be made for omalizumab diators. Therefore, it makes logical sense that http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Pediatrics American Medical Association

Omalizumab for Atopic Dermatitis

JAMA Pediatrics , Volume 174 (1) – Jan 25, 2020

Loading next page...
 
/lp/american-medical-association/omalizumab-for-atopic-dermatitis-a00494x2bt
Publisher
American Medical Association
Copyright
Copyright 2019 American Medical Association. All Rights Reserved.
ISSN
2168-6203
eISSN
2168-6211
DOI
10.1001/jamapediatrics.2019.4509
Publisher site
See Article on Publisher Site

Abstract

Opinion EDITORIAL Overtreatment or Lifesaver? Ann Chen Wu, MD, MPH Atopic dermatitis is a chronic inflammatory skin disease siderable price discounts or medication targeted to specific se- that affects 15% to 20% of children and 1% to 3% of adults vere subgroups. No studies have been conducted to establish worldwide. Omalizumab, a medication administered by the cost-effectiveness of omalizumab for atopic dermatitis, but subcutaneous injection every 2 to 4 weeks, was approved for with current pricing, omalizumab for this purpose may not be moderate-to-severe persis- cost-effective. In general, asthma is a more severe disease than tent asthma in patients aged atopicdermatitis.Asthmawasthecauseof383 000deathsworld- Related article page 29 6 years or older by the US wide in 2015 according to the World Health Organization, com- Food and Drug Administration in 2003. Atopic dermatitis in pared with a slightly increased risk of death from other diseases children is often IgE mediated, and omalizumab is an anti- in patients with atopic dermatitis. Multiple cost-effectiveness IgE medication that binds to human IgE and thus limits mast studiesofasthmarecommendreducingomalizumabcoststojus- cell degranulation and inhibits the release of inflammatory me- tify its use; the same argument could be made for omalizumab diators. Therefore, it makes logical sense that

Journal

JAMA PediatricsAmerican Medical Association

Published: Jan 25, 2020

References